Zohre Naderi

Zohre Naderi

Auto-generated profile, based on publicly available information

Zohre Naderi

Department of Internal Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2020 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
MEMaryam Edalatifard
Maryam Edalatifard
MAMaryam Akhtari
Maryam Akhtari
MSMohammadreza Salehi
Mohammadreza Salehi
ZNZohre Naderi
Zohre Naderi
AJAhmadreza Jamshidi
Ahmadreza Jamshidi
ARAbdolrahman Rostamian
Abdolrahman Rostamian
Introduction: There are no determined treatment agents for severe COVID-19. It is suggested that methylprednisolone, as an immunosuppressive treatment, can reduce the inflammation of the respiratory system in COVID-19 patients.Methods: We conducted a single-blind, randomised controlled clinical trial involving severe hospitalised patients with confirmed COVID-19 at the early pulmonary phase of the illness in Iran. The patients were randomly allocated in a 1:1 ratio by the block randomisation method to receive standard care with methylprednisolone pulse (intravenous injection, 250 mg·day−1for 3 days) or standard care alone. The study end-point was the time of clinical improvement or death, whichever came first. Primary and safety analysis was done in the intention-to-treat (ITT) population.Results: 68 eligible patients underwent randomisation (34 patients in each group) from April 20, 2020 to June 20, 2020. In the standard care group, six patients received corticosteroids by the attending physician before the treatment and were excluded from the overall analysis. The percentage of improved patients was higher in the methylprednisolone group than in the standard care group (94.1%versus57.1%) and the mortality rate was significantly lower in the methylprednisolone group (5.9%versus42.9%; p<0.001). We demonstrated that patients in the methylprednisolone group had a significantly increased survival time compared with patients in the standard care group (log-rank test: p<0.001; hazard ratio 0.293, 95% CI 0.154–0.556). Two patients (5.8%) in the methylprednisolone group and two patients (7.1%) in the standard care group showed severe adverse events between initiation of treatment and the end of the study.Conclusions: Our results suggest that methylprednisolone pulse could be an efficient therapeutic agent for hospitalised severe COVID-19 patients at the pulmonary phase.

10 May 2023 in Clinical Case Reports
Verified
Journal Article
Open access
SSSomayeh Sadeghi
Somayeh Sadeghi
SMShadi Reisizadeh Mobarakeh
Shadi Reisizadeh Mobarakeh
MMMahnaz Momenzadeh
Mahnaz Momenzadeh
AAAmir Aria
Amir Aria
MHMitra Heidarpour
Mitra Heidarpour
ZNZohreh Naderi
Zohreh Naderi
Key Clinical Message: Sarcoidosis is a systemic inflammatory disease able to affect any organ within the body. Sarcoidosis may be the body's secondary response to COVID‐19 infection and a sign of rehabilitation. Early response to the treatments reinforces this hypothesis. The majority of sarcoidosis patients require immunosuppressive therapies, including corticosteroids. Most studies so far have focused on the management of COVID‐19 in patients suffering from sarcoidosis. Nevertheless, the current report aims to present a COVID‐19‐induced sarcoidosis case. Sarcoidosis is a systemic inflammatory disease with granulomas. Still, its etiology is unknown. It often affects the lungs and lymph nodes. A previously healthy 47‐year‐old female was referred with the following chief complaints: atypical chest pain, dry cough, and dyspnea on exertion within a month after COVID‐19 infection. Accordingly, a chest computed tomography revealed multiple conglomerated lymphadenopathies in the thoracic inlet, mediastinum, and hila. A core‐needle biopsy from the nodes revealed non‐necrotizing granulomatous inflammation, sarcoidal type. The sarcoidosis diagnosis was proposed and confirmed by a negative purified protein derivative (PPD) test. Accordingly, prednisolone was prescribed. All symptoms were relieved. A control lung HRCT was taken 6 months later, showing the lesions had disappeared. In conclusion, sarcoidosis may be the body's secondary response to COVID‐19 infection and a sign of disease convalescence.

6 October 2021 in Journal of Renal Injury Prevention
Verified
Journal Article
Open access
SSSomayeh Sadeghi
Somayeh Sadeghi
EKElaheh Keivany
Elaheh Keivany
ZNZohre Naderi
Zohre Naderi
SPSamane Purajam
Samane Purajam
ENElahe Nasri
Elahe Nasri
Introduction: Electrolyte abnormalities are among the most common complications among the patients admitted with coronavirus disease 2019 (COVID 19) pneumonia and maybe contributed to its course of disease and severity. Objectives: The current study aims to assess the prevalence and association of electrolyte imbalance among patients with COVID 19 pneumonia. Patients and Methods: The current observational study has been conducted on 323 patients with COVID 19 pneumonia. On-admission blood samples were taken to assess electrolytes (sodium, potassium, calcium, and magnesium), complete blood count and differentiation (CBC with diff), and other biomarkers. Further measurements of electrolytes were conducted during the period of hospitalization if needed. The frequency and association of electrolyte imbalance with diverse demographic, clinical, laboratory, and in-hospital characteristics was assessed. Results: Hypo/hypernatremia, hypo/hyperkalemia, hypo/hypermagnesemia and hypo/ hypercalcemia were presented in 14.5%/9.4%, 3.8%/10.3%, 7.9%/9.3%, and 10.9%/10.8%, respectively. Time to discharge was remarkably higher among the patients with hypernatremia (P=0.031). The patients with hypermagnesemia were significantly younger than the other cases (P=0.016). The C-reactive protein (CRP) level was statistically less among the patients with hypercalcemia (P=0.025). There was no associative outcome between potassium abnormalities and patients’ characteristics. Conclusion: The present study showed that electrolyte imbalances are common laboratory abnormalities during COVID-19. However, we found no associative role, since ions balance plays a crucial prognostic role for COVID-19.

6 April 2021 in Immunopathologia Persa
Verified
Journal Article
Open access
PDF file
ZNZohre Naderi
Zohre Naderi
BSBahar Sadeghi
Bahar Sadeghi
ZFZiba Farajzadegan
Ziba Farajzadegan
RSRamin Sami
Ramin Sami
MSMansour Salesi
Mansour Salesi
BABabak Amra
Babak Amra
Introduction: Rheumatoid arthritis (RA) is a systemic autoimmune disease with substantial morbidity and mortality. Anti-malarial drugs like hydroxychloroquine are indicated in several rheumatic diseases such as RA. Some reports have suggested hydroxychloroquine for prevention of COVID-19. Objectives: Whether hydroxychloroquine has prophylactic effects for COVID-19 in rheumatic patients. Patients and Methods: In this multicenter cohort-based observational study the preventive effect of hydroxychloroquine regarding the incidence and severity of COVID-19 was investigated in patients with RA who referred to rheumatology clinics of academic hospitals of Isfahan between April and July 2020 and already have been treated with hydroxychloroquine for more than three months. Around 215 patients with RA and current use of hydroxychloroquine were recruited and followed for three months. Patients’ information was gathered using the medical record or by phone call. Results: The incidence of COVID-19 in this selected sample was 4.2% (n=9). Only one in nine patients needed hospitalization, without need for intubation or ICU care. Symptoms including dry cough, headache, body pain, malaise, dyspnea, fever, sore throat, chills, and chest pain, were reported to be statistically higher in COVID-19+ group. Conclusion: In contrast to the mortality rate in the general population of Isfahan, Iran (4.8% - until June 2020), no mortality has been reported in these patients. Therefore, it seems that the use of hydroxychloroquine has been able to reduce the incidence and severity of the disease after reaching steady-state levels. This finding has clinical importance, especially for rheumatic patients using immunomodulatory drugs.

19 November 2021 in Immunopathologia Persa
Verified
Journal Article
Open access
ZNZohre Naderi
Zohre Naderi
MTMarzieh Tajmirriahi
Marzieh Tajmirriahi
KDKian Dolatshahi
Kian Dolatshahi
HHHurieh Hashemi
Hurieh Hashemi
SSSomayeh Sadeghi
Somayeh Sadeghi
MMMarjan Mansourian
Marjan Mansourian
Introduction: Hydroxychloroquine, one of the challenging drugs used for COVID-19, has shown to be beneficial in some studies, although concerns about the side effects of the drug have limited its use. Several electrocardiogram changes have been described in these patients which could be exacerbated using hydroxychloroquine, especially QT-prolongation. Struggles to identify the population at risk of side effects of these drugs result in few scoring systems, one of which is the Tisdale score that showed to have successfully predicted the at-risk population. Objectives: In this study, we aimed to assess the degree of QT prolongation provoked by hydroxychloroquine, either alone or in combination with azithromycin in association with the treatment outcomes based on their Tisdale score. Patients and Methods: We conducted a historical cohort study on 659 patients with COVID-19 at Khorshid hospital, Isfahan, Iran from March to April 2020. Tisdale risk score was used for predicting high-risk patients for QT corrected (QTc) interval prolongation. Results: Mean (SD) of baseline QTc was 390.66 (14.65), 390.74 (16.52), 389.67 (19.51), 390.68 (17.35) for patients who received hydroxychloroquine, hydroxychloroquine plus azithromycin, Kaletra, respectively. QTc was not increased significantly after starting treatment in each group. Conclusion: Despite that none of our patients have a high Tisdale score, our findings showed the predictive value of this score for treatment outcomes. Individuals with medium Tisdale scores showed much worse outcomes and in-hospital mortality. Tisdale score could be employed as a valuable tool to predict the COVID-19 patients’ prognosis after treatment with QT-prolonging drugs.

17 February 2021 in Immunopathologia Persa
Verified
Journal Article
Open access
RSRamin Sami
Ramin Sami
ZKZahra Khani Khoozani
Zahra Khani Khoozani
MMMarjan Mansourian
Marjan Mansourian
ZNZohre Naderi
Zohre Naderi
MKMehdi Karami
Mehdi Karami
NSNafiseh Shokri
Nafiseh Shokri
Introduction: Recently, a high percentage of post-discharge patients have reported persistent symptoms after COVID-19 recovery. However, there is limited comprehensive information regarding nature’s symptoms and association with potential factors. Objectives: We aimed to assess the inpatients’ characteristics and the prevalence of COVID-19 symptoms at admission and four weeks after recovery to recognize the potential factors related to the persistent symptoms. Patients and Methods: We assessed the medical information of 262 severe and 546 non-severe COVID-19 inpatients at admission, and during the first and four weeks after post-discharge from the Khorshid COVID Cohort (KCC) study. Results: Cough, dyspnea, and fatigue were the most reported symptoms at admission, and continuously were declined over the time (all P<0.01). However, the complaint of weight loss was increased during follow-up (P=0.01). Older age (P<0.0001), male gender (P=0.02), administration of hydroxychloroquine (P=0.017), and the interval time from illness onset to visit hospital (P<0.0001) augmented the remaining respiratory symptoms risk. Additionally, more length of hospital stay correlated to the lower risk of persistent constitutional symptoms (P<0.05). Conclusion: This study points out the greater rehabilitation needs and management of persistent symptoms, in particular cough, dyspnea, fatigue and weight loss, and their related factors.